Global state: No clinically significant response (as defined by the original studies) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Global state: 1. No clinically significant response in global state (2‐10 weeks) vs. high dose (> 15‐35 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. high dose (> 15‐35 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Specific behaviour ‐ agitation · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes mental state/behaviour: clinically significant agitation (2‐10 weeks) compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Intervention not reported
Etanercept (25 mg) + DMARD · participants with rheumatoid arthritis
The intervention leads to higher etanercept (25 mg) + DMARD (high certainty).
1 finding from 1 review
Intervention not reported
Etanercept (25 mg) · participants with rheumatoid arthritis
The intervention leads to higher etanercept (25 mg) (high certainty).
1 finding from 1 review
Intervention not reported
Etanercept (25 mg) + DMARD · participants with rheumatoid arthritis
1 finding from 1 review
Intervention not reported
Etanercept (25 mg) · participants with rheumatoid arthritis
1 finding from 1 review
Pain‐free at 2 hours · migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Headache relief at 2 h · migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Sustained pain‐free at 24 h · migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Sustained headache relief at 24 h · migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Number of participants reporting an adverse event · migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Serious AE · migraine headache ‐ moderate or severe pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relief of bleedingdichotomic · patients with uterine fibroids
Mifepristone (5 mg/day/6 months) showed no clear difference in relief of bleedingdichotomic compared with placebo (low certainty).
1 finding from 1 review
Leiomyoma volume (mL) · patients with uterine fibroids
1 finding from 1 review
Uterine volume (cm³) · patients with uterine fibroids
1 finding from 1 review
All studies · patients with the initiation of oral anticoagulation
It is very uncertain whether 5 mg changes all studies compared with 10 mg (very low certainty).
1 finding from 1 review
Single INR measure · patients with the initiation of oral anticoagulation
It is very uncertain whether 5 mg changes single INR measure compared with 10 mg (very low certainty).
1 finding from 1 review